Pfizer Inc., a cornerstone of the pharmaceutical industry, recently experienced a stock dip to around $25, below pre-COVID-19 levels. This presents a compelling buying opportunity at a key technical level of $26. Pfizer's profile is appealing as a long-term investor prioritizing low-risk and consistent dividend payments. The company currently boasts a record-high dividend yield of 5.5%, and we recently received our first dividend payment of $0.42 per share.
Today, $PFE (Pfizer) announced its latest quarterly results with Expectations for 2024 Sales Of $59.5B-$62.5B Compared To Prior Guidance Of $58.5B-$61.5B And Consensus Of $60.668B The company plans to cut costs, which is expected to boost Adjusted EPS Of $2.45-$2.65 Compared To Prior Guidance Of $2.15-$2.35 And Consensus Of $2.37to around These robust earnings results confirm the perfect timing of my investment one month ago.
As one of the largest pharmaceutical companies, Pfizer gained significant recognition for developing the first COVID-19 vaccine and dominating the market during the pandemic. With a PS ratio of around 3, the current price is exceptionally attractive for such a reputable and profitable company. This makes Pfizer a strategic choice for investors seeking stability and growth.
I want to congratulate everyone who followed and copied my trades. We are currently sitting on a 15% profit with our trade, while also enjoying this substantial dividend. We will see how the market reacts to these stellar results after it opens today, we might see bigger movements.
$PFE$ABBV (AbbVie Inc)$BNTX (BioNTech SE-ADR)$AZN.L (AstraZeneca)$DXCM (DexCom Inc)$BMY (Bristol-Myers Squibb Co)$AMGN (Amgen Inc)... Show More
